Reduction Of Screen Failures In A Biomarker- And Cognition-Gated Alzheimer's Disease Trial Through Prescreening And Rapid Operational Activation

Alzheimer’s disease trials often face steep operational hurdles, especially when eligibility depends on biomarker confirmation and precise cognitive thresholds. These constraints are essential for scientific rigor, yet they frequently lead to high screen failure rates, added burden for participants, and slower enrollment. This case study highlights how a targeted prescreening approach can transform trial efficiency in a biomarker- and cognition‑gated AD study.

By engaging a patient pool already characterized for pTau positivity and cognitive impairment, the team shifted effort toward identifying highly probable qualifiers before formal screening began. This upstream alignment sharply reduced the likelihood of non‑eligible candidates entering the funnel and allowed site staff to focus on accurate execution rather than repeated, low‑yield screens.

The results were substantial: screen failures dropped from 50% to just 10, enabling faster enrollment and reducing operational waste. The case underscores how thoughtful prescreening, combined with rapid site activation, can mitigate common pitfalls in AD research—particularly in studies with restrictive biomarker requirements.

Sponsors planning complex CNS or AD trials can use these insights to design more predictable, resource‑efficient enrollment strategies grounded in realistic patient matching.